

CLAIM LISTING

Claims 1-23. (Cancelled)

24. (Currently Amended) A preparation for stimulating or enhancing an immune system, comprising a food product or a drink comprising zinc, ~~[[and]]~~ at least one agent selected from the group consisting of chlorogenic acid and functional analogs thereof, said agent stimulating T-lymphocytes *in vivo*, and at least one polysaccharide selected from the group consisting of β -1,3-glucans, arabinogalactans, and polysaccharides isolated from *Echinacea* species, *Thuja occidentalis*, *Panax ginseng*, fungi, *Aranica montana* cell cultures, *Plantago spp.*, *Achyrocline satureioides*, *Aconitum officinalis*, *Angelica acutiloba*, *Aristolochia officinalis*, *Astragalus gummerifa*, *A. membranaceus*, *A. mongholicus*, *Avena sativa*, *Banbusa vulgaris*, *Baptista tinctoria*, *Bryonia dioica*, *Calendula officinalis*, *Carthamus tinctorius*, *Chamomilla recutita*, *Echinacea angustifolia*, *E. pallida*, *E. purpurea*, *Eleutherococcus senticosus*, *Eupatorium cannabrinum*, *Silene vulgaris*, *Triticum sativum*, *Vincetoxicum officinalis*, and *Viscum album*.

wherein the weight to weight ratio of chlorogenic acid and functional analogs thereof to zinc is in the range of 0.0025 to 500.

25. (Cancelled)

26. (Cancelled)

27. (Currently Amended) A preparation according to claim 24 ~~[[26]]~~, wherein the arabinogalactan is selected from the group consisting of arabinogalactans from ~~*Baptisa*~~ *Baptista tinctoria*, *Echinacea* species, *Larix occidentalis* and *Angelica acutiloba*.

28. (Previously Presented) A preparation according to claim 24, wherein the zinc is present in an effective amount to be capable of inducing the production of interferon-gamma *in vivo*.

29. (Cancelled)

30. (Previously Presented) A preparation according to claim 24, wherein said ratio is in the range of 0.0025 to 2.5.

31. (Previously Presented) A preparation according to claim 30, wherein said ratio is in the range of 0.5 to 2.5.

32. (Previously Presented) A preparation according to claim 24, wherein said ratio is in the range of 0.5 to 500.

33. (Previously Presented) A preparation according to claim 24 comprising: (i) 10-200 mg of chlorogenic acid and/or functional analogs thereof and (ii) 1-200 mg zinc.


34. (Previously Presented) A preparation according to claim 24, wherein the zinc is included as an inorganic zinc salt

35. (Previously Presented) A preparation according to claim 34, wherein the zinc salt is selected from the group consisting of zinc carbonate, zinc sulfate, zinc oxide, zinc chloride and mixtures thereof.

36. (Previously Presented) A preparation according to claim 34, wherein the zinc salt is included as zinc citrate.


37. (Previously Presented) A preparation according to claim 24, wherein said functional analog is selected from the group consisting of chlorogenic acid, 4-caffeoylquinic acid, 5-caffeoylquinic acid and 1,5-dicaffeoylquinic acid, an isochlorogenic acid, 3,4,5 tricaffeoyl quinic acid, 1-O-caffeoylquinic acid, 1,3-O-caffeoylquinic acid), 1,3,4,5-O-tetracaffeoylquinic acid and 5-O-caffeoylshikimic acid.

38. (Previously Presented) A preparation according to claim 24, wherein said agent is a compound represented by formula 1,



(Formula 1)

wherein “a” represents either a single bond or a double bond, and R₁ is only present in case “a” represents a single bond, and wherein at least one of the functional groups R₁-R₄ represents a functional group represented by formula 2



(Formula 2)

and the remaining of said functional groups R₁-R₄ are independently chosen from the group formed by -OH and caffeic acid analogs abundant in a material of a vegetable nature.

39. (Previously Presented) A preparation according to claim 24, wherein said agent originates from one or more plants.

40. (Currently Amended) A preparation according to claim 39, wherein said plant is selected from the group consisting of *Echinacea* sp., *Panax Ginseng*, green coffee bean, green cacao bean, hawthorn, green tea, elder tree, artichoke, ~~guarana~~, guarana, butterbur, Phoenix spp, *Butia capitata*, Dandelion, a dicotylus *Compositae* or other dicotylus, *Arnica montana*, Birch tree and combinations thereof.

41. (Currently Amended) A preparation according to claim 24, further comprising at least one component, other than zinc and polysaccharides, which is capable of inducing the production of interferon-gamma.

42. (Currently Amended) A preparation according to claim 41, wherein said at least one component is ~~selected from the group consisting of N-acetylcysteine and polysaccharides.~~

43. (Currently Amended) A preparation according to claim 24, further comprising at least one additive selected from the group consisting of ginsenosides, antioxidants, trace elements, lipoic acids, L-carnitines, minerals, vitamins, immuno-stimulants, anti-tumor agents and *Astragalus membranaceus* extracts.

44. (Previously Presented) A preparation according to claim 43, wherein the antioxidant is chosen from the group consisting of ascorbic acid, α -tocopherol and combinations thereof.

45. (Previously Presented) A preparation according to claim 43, wherein the trace element is chosen from the group consisting of manganese ions, copper ions, selenium ions, selenium compounds and combinations thereof.

46. (Previously Presented) A preparation according to claim 24, comprising at least one component in the specified amount, selected from the group consisting of 50-2000 mg N-acetylcystein, 200-2000 mg *Echinacea premium*, 0.2-150 mg ginsenosides, 2-200 mg beta glucans, 10-1000 mg ascorbic acid, 1-1000 mg α -tocopherol, 0.1-20 mg copper, 0,005-0.3 mg selenium, 1-100 mg lipoic acid, 10-2000 mg L-carnitine, and *Astragalus membranaceus* extract of 200-20000 mg dry material.

47. (Previously Presented) A preparation according to claim 24 in the form of a capsule, a tablet, a lozenge, a powder, an agglomerate, a paste, a solution, a liquid, a gel, an emulsion, a suspension, a bar, a drink, a pudding, an ice cream or a sauce.

48. (Cancelled)

49. (Withdrawn) A method for treatment and/or prophylaxis of cancer, comprising the use of a preparation according to claim 24.

50. (Withdrawn) A method according to claim 49, wherein zinc is used in an effective amount to induce the production of interferon-gamma.

51. (Withdrawn) A method for treatment and/or prophylaxis of an infection by an infectant, comprising the use of a preparation according to claim 24.

52. (Withdrawn) A method according to claim 51, wherein the infectant is selected from parasites, toxins, viruses, bacteria and combinations thereof.

53. (Withdrawn) A method according to claim 52, wherein the infectant is selected from the group of *Pox-viridae*, *Herpes-viridae*, *Adenoviridae*, *Papavoviridae*, *Hepadnaviridae*, *Parvoviridae*, *Reo-viridae*, *Picornaviridae*, *Toga-viridae*, *Flavi-viridae*, *Corona-viridae*, *Rhabdo-viridae*, *Paramyxo-viridae*, *Orthomixo-viridae*, *Filo-viridae*, *Bunya-viridae*, *Arena-viridae*, *Calici-viridae*, *Retroviridae*, *Papilloma*, *influenza*, HIV, HTLV, Corona, Eppstein Barr, *pneumococci*, *staphylococcus aureus* and combinations thereof.

54. (Withdrawn) A method according to claim 51, wherein the zinc is used in an effective amount to induce the production of interferon-gamma.

55. (Withdrawn) A method for stimulating T-lymphocytes comprising administering a preparation according to claim 24.

56. (Withdrawn) A method according to claim 55, wherein zinc is used in an effective amount to induce the production of interferon-gamma.

57. (Withdrawn) A method according to claim 55, wherein the method is part of a prophylactic or treatment protocol for cancer.

58. (Withdrawn) A method for preparing a product for stimulating T-lymphocytes, comprising the use of a preparation according to claim 24.

59. (Withdrawn) A vaccine comprising chlorogenic acid or a functional analog thereof as adjuvant, said vaccine further comprising zinc.

60. (New) A food product or drink for stimulating or enhancing an immune system, comprising zinc, at least one agent selected from the group consisting of chlorogenic acid and functional analogs thereof, said agent stimulating T-lymphocytes *in vivo*, and at least one polysaccharide selected from the group consisting of β -1,3-glucans, arabinogalactans, and polysaccharides isolated from *Echinacea* species, *Thuja occidentalis*, *Panax ginseng*, fungi, *Aranica montana* cell cultures, *Plantago spp*, *Achyrocline satureioides*, *Aconitum officinalis*, *Angelica acutiloba*, *Aristolochia officinalis*, *Astragalus gummerifa*, *A. membranaceus*, *A. mongholicus*, *Avena sativa*, *Banbusa vulgaris*, *Baptista tinctoria*, *Bryonia dioica*, *Calendula officinalis*, *Carthamus tinctorius*, *Chamomilla recutita*, *Echinacea angustifolia*, *E. pallida*, *E. purpurea*, *Eleutherococcus senticosus*, *Eupatorium cannabinum*, *Silene vulgaris*, *Triticum sativum*, *Vincetoxicum officinalis*, and *Viscum album*,

wherein the daily dose of chlorogenic acid and functional analogs thereof is 0.5-500 mg, and the daily dose of zinc is 1-200 mg.

61. (New) A food product or drink according to claim 60, further comprising N-acetylcysteine, wherein the daily dose of N-acetylcysteine is 50-2000 mg and the daily dose of chlorogenic acid and functional analogs thereof is 2-300 mg.

62. (New) A preparation according to claim 24, wherein the β -1,3-glucan is selected from the group consisting of β -1,3-glucans from the mushrooms *Lentinus edodes* (lentinan), *Schizophyllum commune* (schizophyllan), *Phytophthora parasytica*, *Grifola frondosa*, *Sclerotinia clerotiorum*, *Ganoderma lucidum*, *Coriolus versicolor* (krestin), and from the plants *Morinda citrifolia* fruit and *Viscum Album*.

REMAINDER OF PAGE INTENTIONALLY BLANK